AI Article Synopsis
- The use of circulating tumor cells (CTCs) is gaining recognition as a non-invasive biomarker for cancer diagnosis and treatment.
- Traditional methods for isolating CTCs focus on specific proteins, which can overlook the diversity of cancer cells and limit their prognostic value.
- A new approach using size and deformability for CTC enrichment, specifically with the FDA-approved Parsortix technology, allows for better characterization and may help predict patient responses to therapy in metastatic castration-resistant prostate cancer (mCRPC).
Article Abstract
The clinical utility of circulating tumor cells (CTC) as a non-invasive multipurpose biomarker is broadly recognized. The earliest methods for enriching CTCs from whole blood rely on antibody-based positive selection. The prognostic utility of CTC enumeration using positive selection with the FDA-approved CellSearch system has been demonstrated in numerous studies. The capture of cells with specific protein phenotypes does not fully represent cancer heterogeneity and therefore does not realize the prognostic potential of CTC liquid biopsies. To avoid this selection bias, CTC enrichment based on size and deformability may provide better fidelity, i.e., facilitate the characterization of CTCs with any phenotype. In this study, the recently FDA-approved Parsortix technology was used to enrich CTCs from prostate cancer (PCa) patients for transcriptome analysis using HyCEAD technology. A tailored PCa gene panel allowed us to stratify metastatic castration-resistant prostate cancer (mCRPC) patients with clinical outcomes. In addition, our findings suggest that targeted CTC transcriptome profiling may be predictive of therapy response.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10218842 | PMC |
| http://dx.doi.org/10.3390/ijms24109002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prostate Cancer Risk Prediction Model Using Clinical and Magnetic Resonance Imaging-Related Findings: Impact of Combining Lesions' Locations and Apparent Diffusion Coefficient Values.
J Comput Assist Tomogr
November 2024
From the Department of Radiology, Mayo Clinic, Rochester, MN.
Objectives: The aims of the study are to develop a prostate cancer risk prediction model that combines clinical and magnetic resonance imaging (MRI)-related findings and to assess the impact of adding Prostate Imaging-Reporting and Data System (PI-RADS) ≥3 lesions-level findings on its diagnostic performance.
Methods: This 3-center retrospective study included prostate MRI examinations performed with clinical suspicion of clinically significant prostate cancer (csPCa) between 2018 and 2022. Pathological diagnosis within 1 year after the MRI was used to diagnose csPCa.
Association of radiation-induced normal tissue toxicity with a high genetic risk for rheumatoid arthritis.
J Natl Cancer Inst
January 2025
Translational Radiobiology Group, Division of Cancer Sciences, University of Manchester, The Christie NHS Foundation Trust, Manchester, United Kingdom.
Purpose: Overlapping genes are involved with rheumatoid arthritis (RA) and DNA repair pathways. Therefore, we hypothesised that patients with a high polygenic risk score (PRS) for RA will have an increased risk of radiotherapy (RT) toxicity given the involvement of DNA repair.
Methods: Primary analysis was performed on 1494 prostate cancer, 483 lung cancer and 1820 breast cancer patients assessed for development of RT toxicity in the REQUITE study.
Background: Male pattern baldness (MPB) is commonly associated with prostate diseases, both of which can significantly impact men's quality of life. However, the relationship and causality between them remain unclear. In this study, we investigated the causal relationship between the two.
View Article and Find Full Text PDFIdentification and Validation of Alkaliptosis Resistance-Associated Genes in Prostate Cancer Via Transcriptome Sequencing and Prediction of Biochemical Recurrence.
Mol Biotechnol
January 2025
Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, China.
Androgen deprivation therapy (ADT) is the primary treatment strategy for prostate cancer. However, despite an initially favorable response, tumors inevitably progress to castration-resistant prostate cancer (CRPC). Therefore, the exploration of new therapeutic approaches targeting CRPC has become imperative.
View Article and Find Full Text PDFRacial/ethnic differences in trends of testicular germ cell tumor incidence in the United States, 1992-2021.
Cancer
January 2025
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Background: Testicular germ cell tumors (TGCTs) are the most common cancers among young men in the United States. Incidence rates among non-Hispanic White (NHW) men historically have been much higher than the rates among other men. To study whether this pattern had changed, the authors examined trends in TGCT incidence for the years 1992-2021.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!